Evidence map›Paper›PMID 37158302›Full record

ArticleStatistics in medicine2023

A Bayesian multi-arm multi-stage clinical trial design incorporating information about treatment ordering.

Alessandra Serra, Pavel Mozgunov, Thomas Jaki

Open access · hybridAbstract read
In one paragraph

Article in Statistics in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Alessandra SerraMRC Biostatistics Unit, University of Cambridge, Cambridge, UK.ORCID 0000-0001-8431-5154
Pavel MozgunovMRC Biostatistics Unit, University of Cambridge, Cambridge, UK.ORCID 0000-0001-6810-0284
Thomas JakiMRC Biostatistics Unit, University of Cambridge, Cambridge, UK.ORCID 0000-0002-1096-188X
University of Cambridge · GB

Funding

Department of Health BRC-1215-20014Department of Health NIHR300576Medical Research Council MC_UU_00002/14Medical Research Council MC_UU_00002/19
6 · The paper itself

Abstract

Multi-Arm Multi-Stage (MAMS) designs can notably improve efficiency in later stages of drug development, but they can be suboptimal when an order in the effects of the arms can be assumed. In this work, we propose a Bayesian multi-arm multi-stage trial design that selects all promising treatments with high probability and can efficiently incorporate information about the order in the treatment effects as well as incorporate prior knowledge on the treatments. A distinguishing feature of the proposed design is that it allows taking into account the uncertainty of the treatment effect order assumption and does not assume any parametric arm-response model. The design can provide control of the family-wise error rate under specific values of the control mean and we illustrate its operating characteristics in a study of symptomatic asthma. Via simulations, we compare the novel Bayesian design with frequentist multi-arm multi-stage designs and a frequentist order restricted design that does not account for the order uncertainty and demonstrate the gains in the sample sizes the proposed design can provide. We also find that the proposed design is robust to violations of the assumptions on the order.

Indexed as

Research DesignBayes TheoremClinical Trials as TopicHumansSample Sizeadaptive designsBayesian inferenceinfectious diseasesmulti-arm multi-stageorder restriction

Identifiers

PMID37158302
PMCPMC10962588
OpenAlexW4375955682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.